The t(6;9)-positive acute myeloid leukemia (AML) is classified as a separate clinical entity because of its early onset and poor prognosis. The hallmark of t(6;9) AML is the expression of the DEK/CAN fusion protein. The leukemogenic potential of DEK/ CAN has been called into question, because it was shown to be unable to block the differentiation of hematopoietic progenitors. We found that DEK/CAN initiated leukemia from a small subpopulation within the hematopoietic stem cell (HSC) population expressing a surface marker pattern of long-term (LT) HSC. The propagation of established DEK/CAN-positive leukemia was not restricted to the LT-HSC population, but occurred even from more mature and heterogeneous cell populations. This finding indicates that in DEK/CAN-induced leukemia, there is a difference between 'leukemia-initiating cells' (L-ICs) and 'leukemia-maintaining cells' (L-MCs). In contrast to the L-IC cells represented by a very rare subpopulation of LT-HSC, the L-MC seem to be represented by a larger and phenotypically heterogeneous cell population.
Introduction
Acute myeloid leukemia (AML) is characterized by an abnormal accumulation of hematopoietic progenitors in the bone marrow (BM). The AML phenotype is maintained by an accelerated proliferation of blast cells supported by the aberrant stem-cell capacity of poorly defined leukemic stem cells, and a block in differentiation that prevents progenitors from reaching the postproliferative stage. 1 AMLs are frequently associated with specific chromosomal translocations, resulting in the generation of chimeric genes that encode aberrant fusion proteins, also called leukemia-associated fusion proteins. 2 In models using primary hematopoietic stem cells (HSCs), both the blocking of differentiation and the aberrant stem-cell capacity are strictly dependent on the presence of leukemia-associated fusion proteins. In fact, the ectopic expression of leukemia-associated fusion proteins, such as PML/RARa, PLZF/RARa or AML-1/ETO in hematopoietic progenitor cells recapitulates the leukemic phenotype. [3] [4] [5] The t(6;9)(p23;q34) translocation occurs in 1-5% of adult patients with AML. 6 It is associated with a poor prognosis and defines a high-risk group of AML patients. 6, 7 Although the median age of AML is over 60 years, the median age of patients with t(6;9)-positive AML is approximately 25-30 years. 8 Moreover, t (6;9) represents the only detectable chromosomal aberration at diagnosis in the majority of patients. 7 Although additional karyotypic aberrations are rare, they may appear during disease progression. 7, 9 As a result of the translocation, the 3 0 part of the can gene from chromosome 9q34 is fused to the 5 0 end of the dek gene on chromosome 6p23, resulting in the formation of a chimeric dek/ can fusion gene on the 6p-derivative. The breakpoints on chromosomes 6 and 9 are located in one specific intron on each chromosome. Hence, the resulting fusion gene encodes a single transcript of 5.5 kb that is translated into the DEK/CAN fusion protein with a molecular weight of approximately 165 kDa. 7, 10 The reciprocal CAN/DEK fusion transcript is not detectable in t(6;9)-positive patients. Therefore, DEK/CAN is considered the unique product of t(6;9). 11 The dek gene on chromosome 6 encodes a 375 amino-acid protein with an estimated molecular mass of 43 kDa that has not been classified into a known protein family. DEK is a nuclear protein that is associated with chromatin throughout the cell cycle. It acts as a repressor of transcription by interfering with histone acetyl-transferases 12, 13 and as an activator of transcription by stimulating the binding of the activator protein AP2-a to its target DNA sequences. 13 Furthermore, DEK introduces supercoils into circular DNA and induces intermolecular interactions between two or more DNA molecules through multimerization of DEK-DNA complexes. 14, 15 The overexpression of DEK contributes to an increased proliferative life span of primary cells in culture by inhibiting cellular senescence, most likely through the direct regulation of telomerase or p53. 16 Moreover, the DEK portion of the DEK/CAN fusion protein contains all the major functional domains of DEK ( Figure 1a) .
The can gene encodes a 214-kDa protein also called Nup214 that is involved in nucleo-cytoplasmic transport as a component of the nuclear pore complex. This protein is asymmetrically localized on the cytoplasmic face of the nuclear pore complex in the short fibers. 17 CAN contains a leucine zipper protein interaction interface, as well as a coiled coil oligomerization interface that mediates anchorage to the nuclear pore complex. 17 The overexpression of CAN in U937 cells induces G0 arrest as a result of a defect in mRNA export and the impaired nuclear transport of factors critical for cell growth and survival. 18 The leucine zipper domain necessary for the nuclear pore complex association is lost in DEK/CAN, whereas the coiled coil oligomerization interface is conserved (Figure 1a) . Expression of DEK/CAN is regulated by the DEK promoter, which is regulated according to the cell cycle. 19 However, it remains unclear whether DEK/CAN exhibits novel functions that allow it to escape regulation.
Nearly nothing is known about the biology of DEK/CAN. The fact that the t(6;9) represents the only genetic aberration seen 11 at diagnosis strongly indicates a decisive role for DEK/CAN in the initiation of leukemia. On the other hand, the leukemogenic potential of DEK/CAN has been called into question because it was shown to be unable to block the differentiation of U937 progenitor cells differently than any other AML-associated fusion proteins. 18 These apparent discrepancies prompted us to investigate the leukemogenic potential of DEK/CAN in a primary model using murine HSCs. On the basis of the hypothesis that the target cell for the leukemic transformation induced by DEK/CAN might be a more primitive progenitor than that represented by U937 cells, and that the differentiation block in t(6;9) leukemia appears at earlier stages in hematopoietic development, we investigated the influence of DEK/CAN on primitive HSCs and definitively characterized the leukemogenic potential of DEK/CAN in t(6;9)-positive AML.
Materials and methods

Plasmids and PCR
The complementary DNA encoding PML/RARa has been described previously. 5 To generate the open reading frame of DEK/CAN, the DEK-and CAN-portions of the DEK/CAN complementary DNA were cloned from peripheral blood mononuclear cells using reverse transcriptase-PCR (RT-PCR) with the following primers containing the indicated restriction sites that are underlined: Dek-Sap-ATG fw Leukemogenesis by the DEK/CAN fusion protein C Oancea et al CGC CAG CCA CC-3 0 . The sequences were then ligated using the indicated restriction enzymes to create the complete open reading frame of DEK/CAN. The sequence of the t(6;9) breakpoint was corrected by 'site-directed mutagenesis'. The sequences of all complementary DNAs were verified by sequencing (data not shown). The resulting complementary DNA was then cloned into the Gateway entry-vector (pENTR1A) containing an in-frame sequence encoding the influenza hemagglutinin epitope as a detection tag (HA-tag). Recombination into the destination vectors was completed using the 'LRclonase' enzyme kit (Invitrogen, Karlsruhe, Germany). All retroviral expression vectors used in this study were based on the bi-cistronic PINCO vectors. PINCO was converted to a Gateway-destination vector by the introduction of a Gateway cassette according to the manufacturer's instructions (Invitrogen). 20 For further detection of the DEK/CAN fusion transcript by RT-PCR, the following primer pair was used with an annealing temperature of 55 1C: Dek fw 5 0 -GCC AAA AGA GAA AAA CCT AAA-3 0 and Can rev 5 0 -GCA AGG ATT TGG TGT GAG AT-3 0 .
Cell lines, cell culture, transfection and western blots
The ecotropic Phoenix packaging cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum, transfected using the calciumphosphate precipitation method according to widely established protocols and analyzed using traditional western blot protocols with anti-RARa (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-hemagglutinin (12CA5; Roche Diagnostics, Mannheim, Germany) antibodies. Blocking and antibody incubation were performed in 5% low-fat dry milk followed by washing in Trisbuffered saline (10 mM Tris-HCl pH 8, 150 mM NaCl) containing 0.1% Tween20 (Tris-buffered saline-T).
Isolation of Sca1
þ /lin À HSCs and cell sorting Sca1 þ /lin À HSCs were isolated from 8 to 12-week-old female C57BL/6N mice (Harlan Winkelmann GmbH, Borchen, Germany) after killing by CO 2 asphyxiation. BM was harvested from the femur and tibia by flushing the bones with a syringe and a 26-gauge needle. The cells were 'lineage depleted' by labeling the cells with biotin-conjugated lineage-specific antibodies against B220, CD3e, Gr-1, Mac-1 and Ter-119 (BD Pharmingen, San Diego, CA, USA). The labeled cells were removed using streptavidin-loaded magnetic-activated cell separation columns. Sca1 þ cells were purified by immunomagnetic beads using the magnetic-activated cell separation columns according to the manufacturer's instructions (Miltenyi, Bergisch-Gladbach, Germany). Before further use, the purified cells were prestimulated for 2 days in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Hyclone/Perbio Science, Bonn, Germany), 1% L-Glutamine, 1% Penicillin/ Streptomycin, mIL-3 (20 ng/ml), mIL-6 (20 ng/ml) and murine stem cell factor (mSCF) (100 ng/ml) (Cell Concepts, Umkirch, Germany). For sorting, the cells were stained with fluorophoreconjugated antibodies against Sca1 þ , c-Kit þ , the lin panel and Flk2 þ , all purchased from BD Pharmingen.
Retroviral infection
Ecotropic Phoenix packaging cells were transfected with retroviral vectors as described earlier. The retroviral supernatant was collected on days 2 and 3 after transfection. The target cells were plated onto retronectin-coated (Takara-Shuzo, Shiga, Japan), non-tissue culture-treated 24-well-plates and incubated with the retroviral supernatant for 3 h at 37 1C in the presence of cytokines (20 ng/ml mIL-3, 20 ng/ml mIL-6 and 100 ng/ml mSCF) (Cell Concepts). The cells were centrifuged at 2200 r.p.m. for 45 min at 32 1C. The infection was repeated four times, and the minimal accepted infection efficiency was 70%, as assessed by the detection of green fluorescent protein-positive cells by flow cytometry. The infection efficiency did not vary more than 10%.
Colony assays for determination of the re-plating efficiency
At day 5 post-infection, Sca1 þ /lin À cells were plated at 5 Â 10 3 cells/mL in methyl-cellulose supplemented with mIL-3 (20 ng/ml), mIL-6 (20 ng/ml) and mSCF (100 ng/ml) for myeloid commitment (StemCell Technologies, Vancouver, Canada). The number of colony forming units (CFUs) was determined on day 10 after plating. The cells were washed from the methylcellulose and stained with specific antibodies for the detection of surface marker expression by flow cytometry. Approximately 5 Â 10 3 cells per plate were re-plated in methyl-cellulose to determine the serial re-plating efficiency. Differentiation was assessed on the basis of the expression of c-Kit, Sca1, Gr-1 and Mac-1 (BD/Pharmingen) by flow cytometry.
Colony forming unitFspleen day 12 assay (CFU-S12)
Sca1
þ /Lin À cells (10 4 ) isolated from C57BL/6N mice were retrovirally transduced and cultivated in semi-solid (methylcellulose) medium supplemented with 10% fetal calf serum, mIL-6, mSCF and mIL-3 for 10 days. The cells were then harvested and inoculated into lethally irradiated (11 Gy) female recipient mice. The inoculated mice were killed 12 days later, and the spleens were either homogenized for the isolation of spleen cells or fixed in Tellysniczky's fixative for colony counting as described previously.
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Competitive re-population assay All animal studies were conducted in accordance with national animal protection laws (Regierungspräsidium DarmstadtFF 39/ 06). The competitive re-population assay was based on the CD45.1FCD45.2 chimerism of C57BL/6N mice as previously described. 22 Immediately after retroviral infection, 1 Â 10 
Transduction/transplantation model of leukemia
Female C57BL/6N mice from 8-12 weeks of age (Harlan Winckelmann, Borchen, Germany) were used as recipients and donors. The recipient mice were sub-lethally irradiated with 8.5 Gy, and the donor cells were inoculated into anesthetized mice by retro-orbital injection. The mice were sacrificed at the first appearance of morbidity, loss of weight (410%), neurological abnormalities, failure to thrive or diarrhea and the BM cells were isolated as described above. Splenocytes were isolated by passing the tissue through a 40-mM nylon cell strainer (BecktonDickinson, Le Pont de Claix, France). Whole BM cells and splenocytes were then cytospun onto glass slides and stained with May-Grü nwald-Giemsa stain. For surface marker analysis, the mononuclear cells were enriched using Ficoll density gradient centrifugation.
Statistical analysis
Statistical significance was determined using the unpaired t-test and Log-rank (Mantel-Cox) test using the GraphPad Prism software (Graph Pad, San Diego, CA, USA).
Results
DEK/CAN leads to a slight decrease in differentiation of murine hematopoietic precursors
To investigate the biology of DEK/CAN and its leukemogenic potential, the complete open reading frame of DEK/CAN (Figure 1a ) was created as described above. Due to difficulties in detecting the DEK/CAN fusion protein by western blotting using commercially available antibodies against DEK or CAN, we fused DEK/CAN to an HA tag (Supplementary Figure 1a) . The ectopic expression of DEK/CAN used a retroviral transduction system on the basis of the PINCO vector as previously described (Supplementary Figure 1a) . 5 The efficient translation and integrity of the DEK/CAN open reading frame was confirmed by in vitro translation (data not shown) and by expression in several cell lines, as well as in Sca1 þ /lin À primary murine HSCs (Supplementary Figure 1b) . In contrast to PML/RARa-positive leukemic mice that showed only a moderate splenomegaly, mice with DEK/CAN-positive leukemia exhibited hepato-splenomegaly, as well as increased size of lymph nodes and thymus. Cytology of the spleen and BM cells revealed a picture of AML (Figure 1d) .
To uncover the effects of DEK/CAN on the HSCs responsible for the leukemogenic potential, we compared the phenotype induced by PML/RARa with that induced by DEK/CAN in Sca1 þ /lin À HSCs regarding differentiation and self-renewal potential. DEK/CAN and PML/RARa were retrovirally expressed in Sca1 þ /lin À HSCs to study the effects on spontaneous, as well as G/GM-CSF-induced differentiation (Figure 2a) , as described previously, 5 using empty vector-transduced (Mock) HSCs as controls. Differentiation was assessed by the morphology of May-Grü nwald-Giemsa-stained cells. In comparison to PML/ RARa, which blocked both spontaneous and GM/G-CSFinduced differentiation, DEK/CAN slightly inhibited spontaneous differentiation as compared with controls, but had no effect on GM/G-CSF-induced differentiation (Figure 2b ).
These data show that the expression of DEK/CAN only slightly blocks the differentiation of a Sca1 þ /lin À bulk population of HSCs. Leukemogenesis by the DEK/CAN fusion protein C Oancea et al
Increased re-plating efficiency is considered to be related to the self-renewal potential of these progenitors. 5, 21, 23 To investigate whether DEK/CAN was able to increase the in vitro re-plating efficiency of HSCs, we retrovirally expressed DEK/ CAN in Sca1 þ /lin À HSCs and seeded the cells in semi-solid medium in the presence of mIL-3, mSCF and mIL-6. PML/RARa was used as a positive control (Figure 3a) . Although DEK/CANpositive cells produced an increased number of CFUs compared with the controls, the expression of DEK/CAN did not increase the re-plating efficiency compared with mock controls. The mock controls were limited to the third cycle of re-plating, whereas PML/RARa-positive HSCs were re-platable at least to the fifth plating cycle (Figure 3b ). The transgene expression was controlled in the CFUs from the first plating by RT-PCR (Figure 3c ). To finally determine the effects of DEK/CAN on the self-renewal potential of early progenitors and short-term repopulating stem cells (ST-HSCs), we inoculated the cells from the first plating into lethally irradiated recipients and performed a CFU-S12 assay (Figure 3a) . The expression of DEK/CAN significantly increased the potency of early progenitors and/or ST-HSCs to induce CFU-S12, even to a higher extent than PML/RARa (Figures 3d and e) .
In summary, these findings indicate that DEK/CAN exerts its effects on a small subpopulation of cells that cannot be distinguished by in vitro assays.
DEK/CAN increases the ST-HSC potential, but not the long-term (LT)-HSC of murine Sca1
þ /lin À HSCs
To investigate whether the effects of DEK/CAN in the CFU-S12 assay are related to an increase of the self-renewal potential of early progenitors or rather act at the stem-cell level, we performed a competitive re-population assay that can distinguish between the LT repopulating capacity (re-population at 6-12 months) and ST capacity (re-population at 3 months) of a given cell population. 24 As shown in Figure 4a þ recipient mice. Chimerism in the peripheral blood was measured after 6 and 12 weeks as an index of the ST capacity of the cells (Figures 4b and c) . The numbers of both DEK/CAN-and PML/RARa-positive cells in the ST re-population were higher than in controls, and the DEK/CAN-mediated effect was statistically significant (Figure 4c) . In contrast to PML/RARa, DEK/CAN did not confer LT-stem-cell capacity, as revealed by the fact that after 12 months, DEK/CAN-positive cells were rarely detected in either the spleen or the BM. However, the expression of PML/RARa conferred significant LT-capacity to the spleen and had a statistically insignificant effect in the BM (Figure 4d) .
Taken together, these data indicate that a bulk population of DEK/CAN-positive Sca1 þ /lin À HSCs exhaust their stem-cell 
DEK/CAN induces leukemia from the
On the basis of our data, we hypothesized that DEK/CAN only induces leukemia in cells comprising a small proportion of the Sca1 þ /lin À population, which are rarely targeted even with a high transduction efficiency. Considering that the entire Sca1 þ /lin À population of HSCs represents less than 1% of the BM mononuclear cells in C57/BL6 mice, we enriched subpopulations of the Sca1 þ /lin À compartment. To select and amplify rare DEK/CAN-positive cells with leukemia-initiating potential, we used a novel approach to select for 'stem-cell fitness'. As schematically illustrated in Figure 5a , we expressed DEK/CAN in Sca1 þ /lin À cells and enriched this population for LT-(lin (Figures 5a and b (Figure 5b ), were seeded in semi-solid medium in the presence of mIL-3, mSCF and mIL-6. As shown in Supplementary Figure 3a , both populations successfully generated colonies, proving that the cells were intact at the moment of seeding. After 10 days, all cells, regardless of whether they formed colonies, were harvested and inoculated into lethally irradiated (11 Gy) mice for a CFU-S12 assay. Given the very low number of cells derived from the LT-HSCs, only three mice (two for colony counting and one for cell preparation) were inoculated, whereas five mice were inoculated with the STHSCs (three for colony counting and two for cell preparation). At day 12, spleens were isolated from the mice and analyzed for the number of colonies or homogenized for cell harvesting. Considering that CFU-S12 mainly detects early progenitors and cells with ST-HSC potential, 24 the fact that cells derived from the colonies from mock-infected ST-HSCs took root and produced a higher number of spleen colonies than mock-infected LT-HSCs represents a good control for the functional integrity of the cells. Nearly no difference was seen between the DEK/CAN-positive LT-HSCs and ST-HSCs in terms of their capacity to induce spleen colonies (Supplementary Figures 3b and c) . Spleens were homogenized and 2 Â 10 5 splenocytes were inoculated into sublethally irradiated (8.5 Gy) recipients. As shown in Figure 5c Leukemogenesis by the DEK/CAN fusion protein C Oancea et al differential transformation potential in LT-HSC as compared with ST-HSC (Figure 5f ). All these data were reproduced twice with similar numbers and results.
In summary, these data show that DEK/CAN is able to initiate leukemia from LT-HSCs and that these leukemias are transplantable, indicating their full malignant transformation.
DEK/CAN-positive leukemia is maintained not only by early HSCs but also by committed progenitors
To investigate whether the cell population that is able to transfer leukemia to recipients in DEK/CAN-positive leukemia is identical to and restricted to the 'leukemia initiating' population identified in the experiments shown above, we analyzed the leukemic cell population for surface marker expression and sorted the principal subpopulation for further transplantation into sublethally irradiated recipients (Figures 6a and b) . Cells from DEK/CAN-positive leukemias were transferred into secondary recipients with a latency of approximately 4 weeks and a penetrance of 100% (Figure 6c ). The established DEK/CANpositive leukemia was largely composed of already committed Sca1 À /c-Kit þ /lin lo cells, which would correspond to a phenotype of common myeloid/lymphoid progenitors, a distribution of subpopulations which clearly differed in comparison to normal BM ( Figure 6b) . As revealed by the Ly5.1-Ly5.2 polymorphism, these leukemic cells represent the majority of the donor cells (data not shown). Given that leukemia-initiating cells (L-ICs) were found within the Sca1 þ /c-Kit þ lin À population, we sorted for Sca1
À /c-Kit þ /lin lo (common myeloid/GMP) and Sca1 þ / c-Kit þ /lin À and inoculated 2000 cells from each into sublethally irradiated recipients. Both populations gave rise to a highly aggressive immature leukemia within 30-40 days. The nearly identical time of leukemia onset strongly suggested that a similar number of cells are able to sustain leukemia 
and seeded in semi-solid medium supplemented with the indicated growth factors. After 10 days, the cells were harvested and inoculated into lethally irradiated recipients. At day 12, the spleens were isolated. Cells were harvested, pooled and inoculated into sublethally irradiated mice to determine their leukemogenic potential. 
) and the healthy mice inoculated with the Sca1
populations, respectively, by western blotting. All data were reproduced twice with similar results.
Leukemogenesis by the DEK/CAN fusion protein C Oancea et al development. The presence of the transgene was confirmed by western blotting (Figure 6d ). Both populations generated an identical phenotype as compared with the primary leukemia with AML without signs of differentiation and full infiltration of lymph nodes, spleen and liver (Figures 6e and f) . On the basis of the findings that in some murine leukemia models L-ICs were found in the B220 þ population, 25 we also sorted for Flk2 and B220 expression and inoculated 2000 of these cells into sublethally irradiated mice. We found that cells from all populations originated leukemia, but the B220 À population not expressing Flk2 gave rise to leukemia in a time frame close to that of common myeloid/GMP or HSC (Figure 6c) .
The very short latency of the leukemia induction, together with our findings that the 'secondary leukemias' resulted in the development of 'tertiary leukemias' from populations other than the Flk2
À populations strongly suggest that the cell population giving rise to the secondary leukemia was not restricted to the small lin
À subpopulation that gave rise to the primary leukemia.
Taken together, these data demonstrate that the Sca1
À LT-HSC population contains the target cells of DEK/CAN-induced transformation, but that the DEK/CANpositive leukemia itself is 'maintained' by cells with a broader spectrum of different cell populations, suggesting that there is a difference between L-ICs and 'leukemia-maintaining cells' (L-MCs).
Discussion
The aim of this study was to definitively answer the question of whether the t(6;9)-associated DEK/CAN fusion protein has leukemogenic potential and from which cell population DEK/ CAN-positive leukemia originates.
The data presented in this study prove that DEK/CAN has leukemogenic potential and that it only exerts its effects on a very small subpopulation of Sca1 þ /lin À cells. These findings explain why DEK/CAN is unable to block terminal differentiation Leukemogenesis by the DEK/CAN fusion protein C Oancea et al of early and committed progenitors and also explain the low penetrance of leukemia from DEK/CAN-transduced Sca1 þ /lin À cells. One of the major features of a cell that is able to initiate leukemia is its 'stem-cell fitness'. 26 In this study, we show that DEK/CAN confers an increased ST, but not an LT-stem-cell capacity to the bulk population of Sca1 þ /lin À cells. This is in contrast to PML/RARa, which is able to confer both ST-and LTstem-cell capacities. These differences were not due to differences in homing as shown by the fact that both DEK/ CAN and PML/RARa produced 2-10% of donor cells in the competitive re-population assay after 6 weeks, confirming the similar effects of fusion proteins on the frequency of the repopulating cells. These data lead to the hypothesis that the differences between DEK/CAN and PML/RARa regarding their effects on 'stemness' in the Sca1 þ /lin À bulk population can be attributed to their differential capacity in avoiding 'stem-cell exhaustion.' The capacity to circumvent 'stem-cell exhaustion' by the induction of p21 cip1/waf1 has been shown to be indispensable for efficient leukemia induction, as recently shown for PML/RARa and AML-1/ETO. 26 In contrast to PML/ RARa, the expression of DEK/CAN in Sca1 þ /lin À is not accompanied by the upregulation of p21 cip1/waf1 in a Sca1 þ / lin À bulk population (data not shown). On the other hand, the fact that DEK/CAN exerts its leukemogenic potential on a very small subpopulation could render its biological effects undetectable in conventional in vitro assays, in contrast to PML/ RARa, which confers 'stem-cell fitness' not only to HSCs but also to already committed progenitors. [26] [27] [28] In fact, upon selection for 'stem-cell fitness,' we were able to enrich a DEK/CAN cell population originating from the LT-HSC compartment. This selection used a novel approach of sorting for cells with LT-HSC (Sca1
surface marker patterns and then plating them in semi-solid medium followed by inoculation in lethally irradiated mice for harvesting of spleen colonies at day 12, which were then inoculated into sublethally irradiated mice for leukemia induction. This approach yielded a cell population with high leukemic potential. At each step, the differences between the Flk2 þ and Flk2 À populations were confirmed, allowing for a well-controlled study. In fact, as expected from immature HSCs, the number of colonies in the semi-solid medium, which allows for the outgrowth of progenitors with proliferative potential, 24 was much lower for the Flk2 À as compared with the Flk2 þ population. This difference was not changed by the expression of DEK/CAN compared with mocktransduced controls. In addition, the higher spleen colony number confirmed the maturation status of the control Flk2 þ cells with respect to the Flk2 À population. In fact, spleen colonies are mainly formed from early progenitors and ST-HSCs. It is interesting that compared with controls, the presence of DEK/CAN reduces the CFU-S12 from the Flk2 þ -population. This finding is most likely due to the proliferative block on the progenitors, as revealed by the PKH26 assay on Sca1 þ /lin À HSCs. These findings provide the first strong evidence that the target cell is decisive for the leukemogenic transformation potential of DEK/CAN. In fact, the DEK/CAN fusion protein was detected not only in the BM of leukemic mice derived from the LT-HSC population but also in that of healthy mice inoculated with the ST-HSC population, which were obviously not transformed by DEK/CAN. Furthermore, these findings provide a valid explanation for why DEK/CAN is unable to block the VitD 3 -induced differentiation of U937 cells; the U937 cells are likely too mature to be influenced by DEK/CAN. Not every tumor cell is a 'tumor-initiating cell.' The 'stochastic model' postulates that every cell in a tumor is able to give rise to a new tumor. However, entry into the cell cycle is a stochastic event with a low probability. 29 This means that tumor cells are biologically homogeneous and that the aberrant genetic or epigenetic programs responsible for tumorigenesis are the same in all cells that form a tumor. The 'hierarchical model' postulates that only a small number of cells possess tumorinitiating potential, predicting that tumor cells possess a functional heterogeneity and that the cells capable of tumorigenesis are a quantitatively small population among the bulk of tumor cells. 29 The capacity of DEK/CAN to initiate leukemia depends on targeting a very small subpopulation within the LT-HSC pool that still does not perfectly encompass the DEK/CANdependent L-IC population, suggesting that DEK/CAN-L-IC respects the hierarchical model. On the other hand, the capacity of subpopulations of the already established leukemia to transfer the disease to secondary recipients provides strong evidence that there is a difference between L-ICs and L-MCs. In our model, leukemia clearly initiates from Sca1 þ /c-Kit þ /lin-/Flk2 
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